| 000 | a | ||
|---|---|---|---|
| 999 |
_c15517 _d15517 |
||
| 003 | OSt | ||
| 005 | 20211120120118.0 | ||
| 008 | 211120b xxu||||| |||| 00| 0 eng d | ||
| 040 |
_aAIKTC-KRRC _cAIKTC-KRRC |
||
| 100 |
_914680 _aRao, Monica Raghavendra Prasad |
||
| 245 | _aSelf-nanoemulsifying Drug Delivery System of Cilnidipine | ||
| 250 | _aVol.55(3), Jul-Sep | ||
| 260 |
_aBanagalore _bAssociation of Pharmaceutical Teachers of India (APTI) _c2021 |
||
| 300 | _a664-676p. | ||
| 520 | _aAim: Self-nanoemulsifying Drug Delivery Systems (SNEDDS) are physically stable, isotropic mixtures of oil, surfactant and co-surfactant. The turbulence generated by peristaltic movements of the GIT causes formation of oil-in-water (o/w) nano-emulsions upon dilution. The objective of this study was to improve solubility and oral bioavailability of Cilnidipine by formulating liquid-SNEDDS. Materials and methods: Capmul PG8 NF, Cremophor RH40, and Transcutol HP were selected as oil, surfactant, and co-surfactant. Ternary phase diagrams were constructed to evaluate the nanoemulsification region. A 32 factorial design was employed to optimize L-SNEDDS with droplet size and drug release as responses. SNEDDS of CLN was evaluated for droplet size, self-emulsification time, in vitro drug release, ex-vivo permeation, pharmacokinetics and tissue distribution studies and stability studies. The optimized L-SNEDDS was converted into solid form using β-cyclodextrin nanosponges as adsorbents and evaluated in terms of micromeritics, drug content, scanning electron microscopy and powder X-ray diffraction. Results: The optimized batch exhibited droplet size of 23.70 nm, and in vitro drug release of 95.24 % in 60 min.The in-vivo studies revealed nearly 5.53 folds increase in AUC0-∞ of optimized batch of liquid SNEDDS compared to CLN which can be credited to increase in solubility and dissolution rate. Conclusion: In vivo studies revealed improved pharmacokinetic properties which were attributed to greater surface area and lymphatic absorption leading to circumvention of hepatic first pass metabolism. | ||
| 650 | 0 |
_94639 _aPHARMACEUTICS |
|
| 700 |
_914681 _a Kulkarni, Sayali |
||
| 773 | 0 |
_tIndian journal of pharmaceutical education and research _dBengluru Association of Pharmaceutical Teachers of India (APTI) _x0019-5464 |
|
| 856 |
_uhttps://www.ijper.org/sites/default/files/IndJPhaEdRes-55-3-664.pdf _yClick here |
||
| 942 |
_2ddc _cAR |
||